KAUST and Oxford study develops blood sensor for Parkinson detection

The preliminary study, which evaluated 59 participants, achieved a 90.9% accuracy rate in distinguishing between molecular patterns associated with the condition and those found in healthy individuals.

Sensor Detects Alpha-Synuclein Protein at Low Concentrations

The sensor was engineered to detect three distinct isoforms of the alpha-synuclein protein simultaneously, measuring them at extremely low concentrations that traditional analytical methods struggle to register.

Changes associated with Parkinson disease may begin long before it is diagnosed clinically, and despite the ease of obtaining blood samples, detecting these changes through them remains a major challenge. The technology we developed allows us to monitor multiple forms of alpha-synuclein at the same time, even when their concentrations in the blood are extremely low, and these preliminary results are encouraging, with our next step being to verify the performance of the technology in much larger numbers of patients.

Professor Şahika İnal

Methodology And Sample Groups

The evaluation utilized blood samples provided by the Oxford Discovery research cohort, with analysts remaining blinded to the health status of the participants. The 59-participant cohort included diagnosed Parkinson patients, healthy control subjects, and individuals suffering from isolated rapid eye movement sleep behavior disorder, a condition linked to an increased risk of developing Parkinson or related neurological disorders.

Measuring these proteins directly in blood has historically presented a major obstacle because more than 95% of the alpha-synuclein circulating in the bloodstream originates from red blood cells, which generates background noise and obscures target signals from the brain. By extracting neuron-derived extracellular vesicles first, the research team bypassed that interference and uncovered distinct patterns among the different protein isoforms across the study groups.

Larger Trials Must Validate Tool for Clinical Use

Parkinson disease damages dopamine-producing nerve cells, leading to disruptions in movement, balance, and other bodily functions. While clinical evaluation currently dictates diagnosis only after motor symptoms appear, early protein detection aims to spot the condition much sooner.

However, investigators emphasize that the technology is not yet ready to serve as a standalone diagnostic blood test due to the retrospective nature of the analysis and the limited sample size. Validating the tool for clinical use requires larger, multi-center trials that track participants over extended periods to confirm both its accuracy and its predictive capability.